This open-label study assessed the pharmacokinetics, safety, and tolerability of milvexian, an oral small molecule inhibitor of factor XIa, in participants with normal renal function and participants with moderate or severe renal impairment.

A single dose of milvexian 60 mg was safe and well tolerated in participants with normal renal function and in those with moderate or severe renal impairment.

Modest increases in milvexian exposure were observed in participants with moderate and severe renal impairment, but these are not likely to be clinically relevant.